File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma

TitleAngiogenesis and antiangiogenic therapy in hepatocellular carcinoma
Authors
KeywordsAngiogenesis
Antiangiogenic therapy
Hepatocellular carcinoma
Vascular endothelial growth factor
Issue Date2006
PublisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/canlet
Citation
Cancer Letters, 2006, v. 242 n. 2, p. 151-167 How to Cite?
AbstractHepatocellular carcinoma (HCC) is a hypervascular tumor characterized by neovascularization, which plays an important role in the growth and progression of HCC. Angiogenesis provides a target for novel prognostic and therapeutic approaches to HCC. Assessment of microvessel density using immunohistochemical staining for specific endothelial cell markers such as CD34 has been shown to provide prognostic information independent of conventional pathological parameters in HCC patients. Recent studies have unveiled the important angiogenic factors involved in the regulation of angiogenesis in HCC, although the exact molecular pathways are far from clear. Current data suggest that vascular endothelial growth factor (VEGF) plays a critical role in angiogenesis of HCC. Tumor expression of VEGF has been shown to correlate with tumor invasiveness and prognosis in patients with HCC. VEGF is an important molecular target for antiangiogenic therapy. Studies in animal models have demonstrated the efficacy of antiangiogenic agents such as anti-VEGF antibody and antagonists of VEGF receptors in suppressing hepatocarcinogenesis and growth of HCC. Antiangiogenic therapy has already entered clinical trials in HCC patients and holds the promise of providing an effective novel treatment for HCC, which is of great clinical significance because there is no existing effective systemic therapy for HCC. © 2006 Elsevier Ireland Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/78406
ISSN
2015 Impact Factor: 5.992
2015 SCImago Journal Rankings: 2.331
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorPang, Ren_HK
dc.contributor.authorPoon, RTPen_HK
dc.date.accessioned2010-09-06T07:42:32Z-
dc.date.available2010-09-06T07:42:32Z-
dc.date.issued2006en_HK
dc.identifier.citationCancer Letters, 2006, v. 242 n. 2, p. 151-167en_HK
dc.identifier.issn0304-3835en_HK
dc.identifier.urihttp://hdl.handle.net/10722/78406-
dc.description.abstractHepatocellular carcinoma (HCC) is a hypervascular tumor characterized by neovascularization, which plays an important role in the growth and progression of HCC. Angiogenesis provides a target for novel prognostic and therapeutic approaches to HCC. Assessment of microvessel density using immunohistochemical staining for specific endothelial cell markers such as CD34 has been shown to provide prognostic information independent of conventional pathological parameters in HCC patients. Recent studies have unveiled the important angiogenic factors involved in the regulation of angiogenesis in HCC, although the exact molecular pathways are far from clear. Current data suggest that vascular endothelial growth factor (VEGF) plays a critical role in angiogenesis of HCC. Tumor expression of VEGF has been shown to correlate with tumor invasiveness and prognosis in patients with HCC. VEGF is an important molecular target for antiangiogenic therapy. Studies in animal models have demonstrated the efficacy of antiangiogenic agents such as anti-VEGF antibody and antagonists of VEGF receptors in suppressing hepatocarcinogenesis and growth of HCC. Antiangiogenic therapy has already entered clinical trials in HCC patients and holds the promise of providing an effective novel treatment for HCC, which is of great clinical significance because there is no existing effective systemic therapy for HCC. © 2006 Elsevier Ireland Ltd. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/canleten_HK
dc.relation.ispartofCancer Lettersen_HK
dc.rightsCancer Letters. Copyright © Elsevier Ireland Ltd.en_HK
dc.subjectAngiogenesisen_HK
dc.subjectAntiangiogenic therapyen_HK
dc.subjectHepatocellular carcinomaen_HK
dc.subjectVascular endothelial growth factoren_HK
dc.titleAngiogenesis and antiangiogenic therapy in hepatocellular carcinomaen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0304-3835&volume=242&issue=2&spage=151&epage=167&date=2006&atitle=Angiogenesis+and+antiangiogenic+therapy+in+hepatocellular+carcinomaen_HK
dc.identifier.emailPang, R: robertap@hkucc.hku.hken_HK
dc.identifier.emailPoon, RTP: poontp@hkucc.hku.hken_HK
dc.identifier.authorityPang, R=rp00274en_HK
dc.identifier.authorityPoon, RTP=rp00446en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.canlet.2006.01.008en_HK
dc.identifier.pmid16564617-
dc.identifier.scopuseid_2-s2.0-33749261599en_HK
dc.identifier.hkuros125158en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33749261599&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume242en_HK
dc.identifier.issue2en_HK
dc.identifier.spage151en_HK
dc.identifier.epage167en_HK
dc.identifier.isiWOS:000241973400002-
dc.publisher.placeIrelanden_HK
dc.identifier.scopusauthoridPang, R=7004376659en_HK
dc.identifier.scopusauthoridPoon, RTP=7103097223en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats